# Semaglutide and C-Reactive Protein: What the Weight and CRP Results Mean

A nine-trial review measured weight, waist circumference and CRP with injectable semaglutide. See what the placebo comparisons can tell us.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/semaglutide-weight-vs-crp-percentages
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Semaglutide and C-Reactive Protein: What the Weight and CRP Results Mean

A pooled analysis found that injectable semaglutide reduced weight, waist circumference and CRP more than placebo. Each outcome measures something different.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Difference in change versus placebo · body weight · −12.04 · percentage points · C-reactive protein · −40.9 · percentage points · Body weight and CRP are different outcomes.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A review pooled nine trials of injectable semaglutide in adults without diabetes.
-   Weight and C-reactive protein fell more with semaglutide than with placebo.
-   The analysis does not establish whether the CRP changes were independent of weight loss.

C-reactive protein, or CRP, is a blood marker of inflammation. Research on [GLP-1 drugs and inflammation](https://buythisglp.com/research/do-glp1-drugs-reduce-inflammation) uses markers like CRP to track changes during treatment. The same percentage change in body weight and CRP would describe different outcomes.

## What the review found

The review included nine trials with 6,239 adults who had overweight or obesity without diabetes [\[1\]](https://buythisglp.com/research/semaglutide-weight-vs-crp-percentages#ref-1). Compared with placebo, semaglutide lowered body weight by 12.04 percentage points more from baseline. The 95% confidence interval for that reduction was 11.00 to 13.08 points. Waist circumference fell 9.36 cm more than with placebo.

The pooled difference in CRP change was 40.90 percentage points in favor of semaglutide [\[1\]](https://buythisglp.com/research/semaglutide-weight-vs-crp-percentages#ref-1). The 95% confidence interval was 35.42 to 46.37 points. The studies used different doses and follow-up periods. The review could not separate the effects of weight loss from other possible causes of the CRP changes.

## What it found about serious adverse events

The pooled risk ratio for serious adverse events was 1.12, with a 95% confidence interval of 0.76 to 1.65 [\[1\]](https://buythisglp.com/research/semaglutide-weight-vs-crp-percentages#ref-1). Studies of [specific digestive side effects](https://buythisglp.com/research/glp1-gallstones-and-reflux-pooled) address a different question from counting all serious events. The interval leaves room for a lower or higher rate with semaglutide.

## Frequently asked

Did semaglutide lower CRP?

The review reported a 40.90-percentage-point greater reduction from baseline than placebo. That result measures a blood marker.

Does the CRP result prove a direct anti-inflammatory effect?

The review could not separate weight-loss effects from other possible causes of the CRP change.

Did serious adverse events differ?

The pooled risk ratio was 1.12, with a 95% confidence interval from 0.76 to 1.65. The estimate remains uncertain.

## Sources

1.  \[1\] Milluzzo A, et al. (2026). Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis International Journal of Obesity. [PMID 42668312](https://www.nature.com/articles/s41366-026-02189-x)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
